Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane.

Not Applicable

• Conditions: gastric cancer

• Registration Number: JPRN-UMIN000018606
• Lead Sponsor: Kobe City Medical Center General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-08-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

1) active synchronous or metachronous malignancy 2) previously treated with irinotecan 3) uncontrolled hypertension 4) active infection 5) serious coexisting illness 6) intensive surgery within 28 days prior to the registration 7) embolism and thrombosis, or grade 3 or more GI bleeding within 3 months prior to the registration 8) uncontrolled diarrhea 9) severe allergy 10) moderate or more pleural effusion/ascites 11) systemic steroid user 12) severe mental disorders 13) symptomatic central metastasis 14) atazanavir user 15) pregnant or nursing 16) active hepatitis 17) UGT1A1*6/*6, *28/*28, *6/*28 18) other conditions not suitable for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified